 |
|
|
| |
Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir
Alafenamide vs Tenofovir Disoproxil Fumarate in Chronic HBV Patients Treated for 2 Years
|
| |
| |
AASLD 2021 Nov 12-15
Scott K. Fung,1 Sang Hoon Ahn,2 Chi-Yi Chen,3 Magdy Elkhashab,• Hie-Won L. Hann,5 Maciej S. Jablkowski,6 Yoon Jun Kim,7 Cihan Yurdaydin,8 Cheng-Yuan Peng,9 Tuan Nguyen,10 Hiroshi Yatsuhashi,11
1University of Toronto, Canada; 2Yonsie Liver Center Severance Hosital, Seoul, Republic of Korea,; 3Ditmanson Medical Foundation Chia-Yi Christian Hospital Chaiyi City, Taiwan; 4Toronto Liver Center, tort; 5Jefferson University Hospitals, Philadelphia, PA; 6Medical University of Lodz, Poland; 7LiverResearch Institute, Seoul National University College of Medicine Seoul; 8ankara Turkey; 9Center for Digestive Medicine China Medical University Hospital, Taichung City, Taiwan; 10 Tuan Ngnyen, MD, Research & Education Inc San Diego, CA; 11 National Hosoital Organization Nagasaki Medical Center, Omura, Japan; 12Kyoto University, Kyoto, Japan; 13Gilead Sciences, Inc. Foster City, CA; 14 UCSG School of Pharmacy, San Francisco, CA; 15 I.M. Schenov First Moscow State Medical University, Moscow, Russia; 16Asian Medical Center, University of Ulsan College of Medicine, Seoul; 17 Hospital Universitari Vall d'Hebron, Barcelona, Spain
|
| |
|
|
|
|
|
